| Literature DB >> 36185687 |
Jiahui Gao1,2, Lixiang Li1,2, Dong Zhao1,2,3, Xia Wang1,2, Yanan Xia1,2, Bing Li1,2, Chang Liu1,2, Xiuli Zuo1,2,4.
Abstract
Intestinal bowel disease (IBD) has always been tough to treat, therefore researchers are struggle to look for treatments that are safe, low cost, and effective. Food-derived peptides are thought to have anti-inflammatory and antioxidant properties, but they have not been studied in depth in the treatment of IBD. Based on this, we explored the effect of tilapia skin peptides (TSPs) on the remission of colitis in the present study. Colonic epithelial cell lines CT-26 and HT-29 were co-treated with lipopolysaccharide (LPS) and TSPs for 12 h. Cell viability was assessed by CCK8 assay. Dextran sulfate sodium (DSS)-induced colitis model was established and 100 mg/kg TSPs were oral administered at the same time as DSS intervention. Colonic mucosal barrier function was assessed by western blotting. The inflammatory responses were evaluated by quantitative real-time PCR along with ELISA, respectively. Apoptosis was investigated by TUNEL and flow cytometry. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to characterize peptides composition of TSPs. It was found that TSPs significantly inhibit LPS-induced inflammation and apoptosis in vitro without affecting cell viability. Moreover, the upregulation and activation of Caspase-3 and Caspase-8 were also reversed by TSPs. Subsequently, in vivo experiments demonstrated that TSPs can attenuate DSS induced colitis, manifested by a decrease in weight loss and colon shortening. The expression of ZO-1 and occluding were significantly increased, and the pro-inflammatory cytokines were down-regulated. Meanwhile, TSPs alleviated DSS-induced apoptosis and reduced the expressions of Caspase-3 and Caspase-8. Finally, we found that TSPs were composed of 51 short peptides, and 12 of them were predicted to have significant biological activity. Collectively, this study suggested that TSPs can alleviate colon damage caused by foreign stimuli via inhibiting inflammation and apoptosis which indicated that it has great potential value for the treatment of IBD.Entities:
Keywords: LC-MS/MS; apoptosis; inflammatory bowel disease; intestinal epithelial homeostasis; tilapia skin peptides
Year: 2022 PMID: 36185687 PMCID: PMC9525210 DOI: 10.3389/fnut.2022.988758
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
FIGURE 5Oral TSPs administration alleviated DSS-induced colitis. (A) Graphical description of experimental design of this study. (B) Daily body weight changes following DSS treatment (n = 8). Statistical significance was determined using two-way ANOVA. **P < 0.01 relative to DSS group; ##P < 0.01, ###P < 0.001 relative to Control group. (C) Macroscopic pictures of colons and (D) the statistical colon length from different groups (n = 8). (E) H& E stained colon sections and (F) histological scores of colons (n = 8). Data were presented as means ± SD. Statistical significance was determined using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
Primer sequence for qPCR.
| Forward | Reverse | |
| miceIL-1β | GAAATGCCACCT | TGGATGCTCT |
| miceIL-6 | CTGCAAGAGA | AGTGGTATAGA |
| miceCASP3 | GGAGTCTGACTG | CTTCTGGCAAG |
| miceCASP8 | ATGGCTACGGT | TAGTTCACGCC |
| miceIL-17A | CAGACTACCTCA | TCCAGCTTTCC |
| miceTNF-α | CAGGCGGTGC | CGATCACCCCGA |
| miceGAPDH | CATCACTGCCAC | ATGCCAGTGAGC |
| humanIL-1β | AGCTACGAATC | CGTTATCCCATG |
| humanIL-6 | ACTCACCTCTTCA | CCATCTTTGGAAGG |
| humanCASP3 | GGAAGCGAATCA | GCATCGACATCTG |
| humanCASP8 | AGAAGAGGGTCA | TCAGGACTTCCT |
| humanGAPDH | GTCTCCTCTGACTTC | ACCACCCTGTTGCTG |
FIGURE 1The cell viability and expression of pro-inflammatory cytokines of mice colonic epithelial cell line CT-26. (A) Cell viability was determined by CCK-8 assay after TSPs treatment (n = 9). (B,C) Relative mRNA expression of two pro-inflammatory cytokines, IL-1β and IL-6 (n = 3). The concentrations of IL-1β (D), IL-6 (E) measured by ELISA (n ≥ 5). Data were presented as means ± SD. Statistical significance was determined using Student’s t-test or one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001; ns, no significance.
FIGURE 2TSPs prevented LPS-Induced Apoptosis in CT-26. (A) Representative images of TUNEL staining in CT-26 cells. Scale bar = 100μm. (B) Quantification of the percentage of TUNEL positive cells (n = 6). (C) Apoptosis analysis of CT-26 cells by flow cytometry. (D) The results of quantitative analyses of apoptosis rate (n = 5). (E,F) Caspase-3 and caspase-8 levels were measured by qRT-PCR (n = 3). (G) Western blot analysis of the cleaved caspase-3 and cleaved caspase-8 proteins in CT-26 cells and semi-quantitative analysis of relative indicated proteins expression (n = 4). Data were presented as means ± SD. Statistical significance was determined using one-way ANOVA. *P < 0.05, ***P < 0.001.
FIGURE 3The cell viability and expression of pro-inflammatory cytokines of human colonic epithelial cell line HT-29. (A) Cell viability was determined by CCK-8 assay after TSPs treatment (n = 9). (B,C) Relative mRNA expression of two pro-inflammatory cytokines, IL-1β and IL-6 (n ≥ 3). The concentrations of IL-1β (D), IL-6 (E) measured by ELISA (n = 6). Data were presented as means ± SD. Statistical significance was determined using Student’s t-test or one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001; ns, no significance.
FIGURE 4TSPs prevented LPS-Induced Apoptosis in HT-29. (A) Representative images of TUNEL staining in HT-29 cells. Scale bar = 100μm. (B) Quantification of the percentage of TUNEL positive cells (n = 6). (C) Apoptosis analysis of HT-29 cells by flow cytometry. (D) The results of quantitative analyses of apoptosis rate (n = 5). (E,F) Caspase-3 and caspase-8 levels were measured by qRT-PCR (n ≥ 3). (G) Western blot analysis of the cleaved caspase-3 and cleaved caspase-8 proteins in HT-29 cells and semi-quantitative analysis of relative indicated proteins expression (n = 5). Data were presented as means ± SD. Statistical significance was determined using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 6Oral TSPs improved the mucosal barrier function and inhibited the expression of inflammatory cytokines. (A) Western blot analysis of the tight junction proteins ZO-1, occludin in the colon. Grayscale statistics of ZO-1 (B) and occluding (C) relative to internal control (n = 8). (D–G) Relative mRNA expression of pro-inflammatory cytokines, IL-1β, IL-6, IL-17A and TNF-α (n = 8). The concentrations of IL-1β (H), IL-6 (I), IL-17A (J) and TNF-α (K) measured by ELISA in the colon (n = 8). Data were presented as means ± SD. Statistical significance was determined using one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
FIGURE 7Oral TSPs reduced DSS-induced apoptosis. (A) Immunofluorescence TUNEL staining of colonic sections. Scale bars = 50 μm. (B) Apoptosis rate in colonic sections (n = 8). (C) Representative images of immunohistochemistry staining for caspase-3 protein. Scale bar = 50 μm. (D) Representative images of immunohistochemistry staining for caspase-8 protein. Scale bar = 50 μm. (E,F) Immunohistochemical image gray-scale analysis of the caspase-3 and caspase-8 of the mean of density (MOD) (n = 8). Data were presented as means ± SD. Statistical significance was determined using one-way ANOVA. ***P < 0.001.
The identified peptides of TSPs.
| Peptide | Modification | Protein origin |
| GPTGPQGPAGPQGLK | Deamidated (NQ)@12Q | C1q domain-containing protein |
| SPMSAFTAALTTPYPPAGSPIK | Oxidation (M)@3M | C1q domain-containing protein |
| SPMSAFTAALTTPYPPAGSPIK | – | C1q domain-containing protein |
| NEEPVLFTYDEYNK | Deamidated (NQ)@1N; deamidated (NQ)@13N | C1q domain-containing protein |
| NEEPVLFTYDEYNK | Deamidated (NQ)@1N | C1q domain-containing protein |
| NEEPVLFTYDEYNK | – | C1q domain-containing protein |
| NEEPVLFTYDEYNK | Deamidated (NQ)@13N | C1q domain-containing protein |
| GPQGPAGQPGSPGMPGVGK | Oxidation (M)@14M | C1q domain-containing protein |
| NGQPVMFTYDEYNK | Oxidation (M)@6M | C1q domain-containing protein |
| NGQPVMFTYDEYNK | – | C1q domain-containing protein |
| NGQPVMFTYDEYNK | Deamidated (NQ)@3Q | C1q domain-containing protein |
| GFLDEMAGSAVLQLYTGDR | Oxidation (M)@6M | C1q domain-containing protein |
| GFLDEMAGSAVLQLYTGDR | – | C2q domain-containing protein |
| DDGNHATVLLLPYK | – | SERPIN domain-containing protein |
| ESGITDAFGDK | – | SERPIN domain-containing protein |
| LSAPNADFAVVLYK | – | SERPIN domain-containing protein |
| TAAGNNIFFSPLGISTALSLLSTGAR | – | SERPIN domain-containing protein |
| LDVGNAAAVR | – | SERPIN domain-containing protein |
| GETGPVGATGPSGPQGSR | – | Fibrillar collagen NC1 domain-containing protein |
| GEGGSFGPAGPAGPR | – | Fibrillar collagen NC1 domain-containing protein |
| FASFIDK | – | IF rod domain-containing protein |
| LALDIEIATYR | – | IF rod domain-containing protein |
| EAYPGDVFYLHSR | – | ATP synthase subunit alpha |
| VIQCSDLGLK | Carbamidomethyl (C)@4C | Decorin |
| QASTADISI | Deamidated (NQ)@1Q | Fibrinogen C-terminal domain-containing protein |
| VGINGFGR | – | Glyceraldehyde-3-phosphate dehydrogenase, EC 1.2.1.12 |
| VIENLTVLK | Deamidated (NQ)@4N | HEPN domain-containing protein |
| VATLQAQLEQSRR | Deamidated (NQ)@5Q; deamidated (NQ)@7Q | Myosin motor domain-containing protein |
| QDWHPFLPK | – | Phospholipid scramblase |
| TVLTQEALISVK | Deamidated (NQ)@5Q | PRELI/MSF1 domain-containing protein |
| EDIGQLVLGAR | Deamidated (NQ)@5Q | Si:ch211–129c21.1 |
| LAADDFR | – | Si:ch211–156l18.7 |
| LEQEIATYR | – | Si:ch211–156l18.7 |
| QKMVEEER | Gln->pyro-Glu (N-term Q)@N_term; deamidated (NQ)@1Q | Wu:fc23c09 |
| SCTLDGQVFADR | Carbamidomethyl (C)@2C | Uncharacterized protein |
| GFPGLPGPSGEPGK | – | Uncharacterized protein |
| VRVPLLVK | – | Uncharacterized protein |
| GIVGLPGQR | – | Uncharacterized protein |
| GEAGAVGVAGPSGPR | – | Uncharacterized protein |
| TFGSCTLDGQLYNDK | Carbamidomethyl (C)@5C | Uncharacterized protein |
| TFGSCTLDGQLYNDK | Carbamidomethyl (C)@5C; deamidated (NQ)@10Q; deamidated (NQ)@13N | Uncharacterized protein |
| VLIELARR | – | Uncharacterized protein |
| MAAVPGVR | – | Uncharacterized protein |
| GESGPSGPAGPAGPAGVR | – | Uncharacterized protein |
| KVLMVGPR | – | Uncharacterized protein |
| SVTLSGIR | – | Uncharacterized protein |
| ILIPLR | – | Uncharacterized protein |
| LPILIDSPK | – | Uncharacterized protein |
| IATALDPR | – | Uncharacterized protein |
| GETGPAGPAGAAGPAGPR | – | Uncharacterized protein |
| IQQSLTSGNLFTVK | Deamidated (NQ)@3Q | Uncharacterized protein |
Activity score results of TSPs.
| Peptide sequence | Score |
| QDWHPFLPK | 0.916566 |
| GESGPSGPAGPAGPAGVR | 0.855864 |
| GPTGPQGPAGPQGLK | 0.837251 |
| GFPGLPGPSGEPGK | 0.83496 |
| GPQGPAGQPGSPGMPGVGK | 0.770195 |
| GETGPAGPAGAAGPAGPR | 0.731973 |
| GEGGSFGPAGPAGPR | 0.711084 |
| FASFIDK | 0.630491 |
| VGINGFGR | 0.612399 |
| ILIPLR | 0.571373 |
| LAADDFR | 0.544243 |
| LSAPNADFAVVLYK | 0.503917 |
FIGURE 8Overview of TSPs inhibiting inflammation and apoptosis caused by external stimuli. (A) TSPs relieved LPS-induced inflammation and apoptosis in vitro. (B) TSPs alleviated DSS-induced inflammation and apoptosis in vivo.